212 related articles for article (PubMed ID: 35651804)
1. CEUS and CT/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma.
Zhou Y; Yin S; Zhao L; Zhang X; Li M; Ding J; Yan K; Jing X
Front Oncol; 2022; 12():897090. PubMed ID: 35651804
[TBL] [Abstract][Full Text] [Related]
2. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
[TBL] [Abstract][Full Text] [Related]
3. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
[TBL] [Abstract][Full Text] [Related]
4. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
5. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Yang J; Zhang YH; Li JW; Shi YY; Huang JY; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Dec; 26(46):7325-7337. PubMed ID: 33362387
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.
Li R; Yang D; Tang CL; Cai P; Ma KS; Ding SY; Zhang XH; Guo DY; Yan XC
BMC Cancer; 2016 Feb; 16():158. PubMed ID: 26917546
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.
Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C
Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940
[TBL] [Abstract][Full Text] [Related]
10. Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥ 2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4.
Kang HJ; Kim JH; Joo I; Han JK
Abdom Radiol (NY); 2020 Jan; 45(1):55-63. PubMed ID: 31332503
[TBL] [Abstract][Full Text] [Related]
11. Correlation between CEUS LI-RADS categorization of HCC < 20 mm and clinic-pathological features.
Yang D; Chen X; Huang L; Wang X; Mao L; Lin L; Han H; Lu Q
Insights Imaging; 2024 May; 15(1):110. PubMed ID: 38713251
[TBL] [Abstract][Full Text] [Related]
12. Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis.
Zhou Y; Qin Z; Ding J; Zhao L; Chen Y; Wang F; Jing X
Front Oncol; 2022; 12():873913. PubMed ID: 35425706
[TBL] [Abstract][Full Text] [Related]
13. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
15. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
[TBL] [Abstract][Full Text] [Related]
16. Compared with CT/MRI LI-RADS, whether CEUS LI-RADS is worth popularizing in diagnosis of hepatocellular carcinoma?-a direct head-to-head meta-analysis.
Wang H; Cao J; Fan H; Huang J; Zhang H; Ling W
Quant Imaging Med Surg; 2023 Aug; 13(8):4919-4932. PubMed ID: 37581040
[TBL] [Abstract][Full Text] [Related]
17. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
18. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.
Li F; Li Q; Liu Y; Han J; Zheng W; Huang Y; Zheng X; Cao L; Zhou JH
Eur Radiol; 2020 Jan; 30(1):461-470. PubMed ID: 31297632
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
Wen R; Lin P; Wu Y; Yin H; Huang W; Guo D; Peng Y; Liu D; He Y; Yang H
Eur J Radiol; 2022 Sep; 154():110415. PubMed ID: 35738166
[TBL] [Abstract][Full Text] [Related]
20. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
